Filing Flows › Si-Bone (SIBN) › Guidance & outlook
Si-Bone (SIBN) guidance and outlook
Si-Bone (SIBN) lowered its guidance on Nov 2, 2026: Revenue $231M–$233M for FY2026; Gross margin 79% for FY2026; Operating expenses +10.5% for FY2026; Revenue +12% for FY2026. Si-Bone's 10-Q filed Nov 3, 2026 makes 11 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $231M–$233M | reaffirmed |
| Gross margin | FY2026 | 79% | reaffirmed |
| Operating expenses | FY2026 | +10.5% | lowered |
| Revenue | FY2026 | +12% | lowered |
From the earnings release filed Nov 2, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 3, 2026
- We are a leader in developing and commercializing differentiated solutions targeting surgical and interventional procedures for patients with compromised bone.
- Since building solutions targeting the sacroiliac joint, we have expanded our platform to address adjacent indications, including spinopelvic fixation, and trauma, leveraging our expertise in biomechanical design and anatomy-specific innovation.
- We intend to make investments to execute our strategic plans and operational initiatives.
- We anticipate certain operating expenses will continue to increase to support our growth.
- Based upon our broader set of product development initiatives and the stage of the underlying projects, we expect to continue to make investments in research and development.
- As such, we anticipate that research and development expenses will continue to increase in the future.
- During the years ended December 31, 2025 and 2024, we incurred a net loss of $18.9 million and $30.9 million, respectively, and expect to incur additional losses in the future.
- Based upon our current operating plan and improved cash flow from operations, we believe that our existing cash and marketable securities will enable us to fund our operating expenses and capital expenditure requirements over the next 12 months from the filing of this Form 10-Q.
- We may face challenges and uncertainties and, as a result, may need to raise additional capital as our available capital resources may be consumed more rapidly than currently expected due to, but not limited to (a) decreases in sales of our products and the uncertainty of future revenues from new products; (b) changes we may make to the
- business that affect ongoing operating expenses; (c) changes we may make in our business strategy; (d) regulatory and reimbursement developments affecting our existing products; (e) changes we may make in our research and development spending plans; and (f) other items affecting our forecasted level of expenditures and use of cash resources.
- (3) Consists of future non-cancelable rent payments under operating lease obligations, excluding expected tenant improvement allowance of $3.8 million related to our San Jose office lease.
Si-Bone's latest quarter
Si-Bone, Q3 2026: revenue $55.7M (+14% year over year), operating margin -7.8%, net loss $3.6M, operating cash flow $5.9M. The chart follows the revenue to costs, profit and cash.
Questions
Did Si-Bone raise or lower its guidance?
Si-Bone (SIBN) lowered its guidance on Nov 2, 2026: Revenue $231M–$233M for FY2026; Gross margin 79% for FY2026; Operating expenses +10.5% for FY2026; Revenue +12% for FY2026.
What does Si-Bone expect?
We are a leader in developing and commercializing differentiated solutions targeting surgical and interventional procedures for patients with compromised bone. Since building solutions targeting the sacroiliac joint, we have expanded our platform to address adjacent indications, including spinopelvic fixation, and trauma, leveraging our expertise in biomechanical design and anatomy-specific innovation. We intend to make investments to execute our strategic plans and operational initiatives.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.